Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models

@inproceedings{Esquejo2018ActivationOL,
  title={Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models},
  author={Ryan M. Esquejo and Christopher T. Salatto and Jake Delmore and Bina Albuquerque and Allan R. Reyes and Yuji Shi and Rob Moccia and Emily C Cokorinos and Matthew Peloquin and Mara Monetti and Jason Barricklow and Eliza Bollinger and Brennan K. Smith and Emily A. Day and Chuong V Nguyen and Kieran F. Geoghegan and John M. Kreeger and Alan C. Opsahl and Jessica S. Ward and Amit S Kalgutkar and David Tess and Lynne D Butler and Norimitsu Shirai and Timothy F. Osborne and Gregory R Steinberg and Morris J Birnbaum and Kimberly O. Cameron and Russell A. Miller},
  booktitle={EBioMedicine},
  year={2018}
}
Dysregulation of hepatic lipid and cholesterol metabolism is a significant contributor to cardiometabolic health, resulting in excessive liver lipid accumulation and ultimately non-alcoholic steatohepatitis (NASH). Therapeutic activators of the AMP-Activated Protein Kinase (AMPK) have been proposed as a treatment for metabolic diseases; we show that the AMPK β1-biased activator PF-06409577 is capable of lowering hepatic and systemic lipid and cholesterol levels in both rodent and monkey… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 19 times. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 45 references

STAR: ultrafast universal RNA-seq aligner

Bioinformatics • 2013
View 1 Excerpt
Highly Influenced

Similar Papers

Loading similar papers…